110 related articles for article (PubMed ID: 11757785)
1. PIV-3 vaccine National Institutes of Health/Aviron.
Jones T
Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
[TBL] [Abstract][Full Text] [Related]
2. Current status of vaccines for parainfluenza virus infections.
Sato M; Wright PF
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
[TBL] [Abstract][Full Text] [Related]
4. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
[TBL] [Abstract][Full Text] [Related]
6. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
Bartlett EJ; Amaro-Carambot E; Surman SR; Newman JT; Collins PL; Murphy BR; Skiadopoulos MH
Vaccine; 2005 Sep; 23(38):4631-46. PubMed ID: 15951066
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
[TBL] [Abstract][Full Text] [Related]
8. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
9. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
[TBL] [Abstract][Full Text] [Related]
10. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults.
Slobod KS; Shenep JL; Luján-Zilbermann J; Allison K; Brown B; Scroggs RA; Portner A; Coleclough C; Hurwitz JL
Vaccine; 2004 Aug; 22(23-24):3182-6. PubMed ID: 15297072
[TBL] [Abstract][Full Text] [Related]
12. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
[TBL] [Abstract][Full Text] [Related]
13. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
[TBL] [Abstract][Full Text] [Related]
14. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
Hall SL; Sarris CM; Tierney EL; London WT; Murphy BR
J Infect Dis; 1993 Apr; 167(4):958-62. PubMed ID: 8383726
[TBL] [Abstract][Full Text] [Related]
15. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
[TBL] [Abstract][Full Text] [Related]
18. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
[TBL] [Abstract][Full Text] [Related]
19. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.
Karron RA; Casey R; Thumar B; Surman S; Murphy BR; Collins PL; Schmidt AC
Pediatr Infect Dis J; 2011 Oct; 30(10):e186-91. PubMed ID: 21829138
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.
Pennathur S; Haller AA; MacPhail M; Rizzi T; Kaderi S; Fernandes F; Bicha L; Schickli JH; Tang RS; Chen W; Nguyen N; Mathie S; Mehta H; Coelingh KL
J Gen Virol; 2003 Dec; 84(Pt 12):3253-3261. PubMed ID: 14645907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
